Drug Profile


Alternative Names: MGN-1703

Latest Information Update: 02 May 2017

Price : $50

At a glance

  • Originator Mologen
  • Developer Aarhus Universitetshospital; Mologen; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; DNA
  • Mechanism of Action Immunomodulators; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Small cell lung cancer
  • Phase I/II HIV-1 infections
  • Phase I Solid tumours

Most Recent Events

  • 25 Apr 2017 Safety and efficacy data from the phase II IMPULSE trial in Small cell lung cancer released by Mologen
  • 22 Mar 2017 Lefitolimod is available for licensing as at 22 March 2017(http://www.mologen.com)
  • 17 Feb 2017 Immunogenicity data from the TEACH phase I/II trial in HIV infections released by MOLOGEN AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top